학술논문
PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)
Document Type
Article
Author
Source
In Annals of Oncology June 2016 27 Supplement 2:ii105-ii105
Subject
Language
ISSN
0923-7534